Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Beobachtungsstudie, um mehr über die Sicherheit von Darolutamid bei Männern mit Prostatakrebs in Korea zu erfahren

4. November 2026 aktualisiert von: Bayer

Post-Marketing-Überwachungsstudie zur zugelassenen Darolutamid-Anwendung bei koreanischen Patienten

This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.

This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth.

To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.

During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors.

Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

600

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Many Locations, Südkorea
        • Rekrutierung
        • Many locations

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

19 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Männlich

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients who have been prescribed Darolutamide for a medically appropriate use will be eligible to be enrolled.

Beschreibung

Inclusion Criteria:

  • Male aged ≥19 years

  • Patients with high risk nmCPRC

    • Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dL])
    • PSA doubling time < 10 months
  • Patients with mHSPC

    • histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
    • be candidates for androgen-deprivation therapy with/without docetaxel.
  • Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice

  • Written informed consent from subject or legal representative; assent from subject when appropriate

Exclusion Criteria:

  • Patients participating in an investigational program with interventions outside of routine clinical practice
  • Participants with contraindication according to the locally approved prescribing information

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Male patients with nmCRPC or mHSPC

Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator.

The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number, severity of adverse events (including SAEs)
Zeitfenster: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SAE stands for serious adverse event. An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Number, severity of adverse drug reactions (including SADRs)
Zeitfenster: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SADR stands for serious adverse drug reaction. An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse events
Zeitfenster: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse drug reactions
Zeitfenster: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Gründe für die Beendigung der Behandlung mit Darolutamid
Zeitfenster: Bis zu 52 Wochen
Bis zu 52 Wochen
Dosierung und Dosisanpassung von Darolutamid
Zeitfenster: Bis zu 52 Wochen
Bis zu 52 Wochen
Metastasis-free survival (MFS) by nmCRPC indication
Zeitfenster: Up to 52 weeks

MFS is defined as the time (months) from the initiation of Darolutamide treatment to the date of first observed metastasis.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by nmCRPC indication
Zeitfenster: Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by nmCRPC indication
Zeitfenster: Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by nmCRPC indication
Zeitfenster: Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to Castration-Resistant Prostate Cancer (CRPC) by mHSPC indication
Zeitfenster: Up to 52 weeks

Time to mCRPC, defined as the time to PSA progression with serum testosterone being at castrate level <0.50 ng/mL, or the time to progression by soft tissue/visceral lesions or time to progression by bone lesions, whatever comes first.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by mHSPC indication
Zeitfenster: Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by mHSPC indication
Zeitfenster: Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by mHSPC indication
Zeitfenster: Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to initiation of subsequent anti-cancer therapy by mHSPC indication
Zeitfenster: Up to 52 weeks

Time to initiation of subsequent anti-cancer therapy is defined as the time (months) from the initiation of Darolutamide treatment to the date of first administration of any subsequent anti-cancer therapy after discontinuation of Darolutamide.

Up to 52 weeks
Radiological progression (Soft tissue/ Bone metastasis) by mHSPC indication
Zeitfenster: Up to 52 weeks

Radiological progression is defined as the time (months) from the start of Darolutamide treatment to the date of first documentation of radiological progressive disease or death due to any cause, whichever occurs first.

Up to 52 weeks
Radiological Progression-Free Survival (rPFS) by mHSPC indication
Zeitfenster: Up to 52 weeks

Radiographic Progression-Free Survival (rPFS) is defined as the time (months) from the initiation of Darolutamide treatment to the date of the first radiologically confirmed disease progression or death from any cause, whichever occurs first.

Up to 52 weeks
Duration of Darolutamide treatment
Zeitfenster: Up to 52 weeks

Duration of Darolutamide treatment is defined as the time (months) from the start of Darolutamide treatment to the day of permanent discontinuation of Darolutamide (including death).

Up to 52 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

25. September 2024

Primärer Abschluss (Geschätzt)

31. März 2028

Studienabschluss (Geschätzt)

30. Juni 2028

Studienanmeldedaten

Zuerst eingereicht

21. März 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. März 2024

Zuerst gepostet (Tatsächlich)

27. März 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. November 2026

Zuletzt verifiziert

4. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 20654

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .